Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 2:12:728734.
doi: 10.3389/fendo.2021.728734. eCollection 2021.

Myokines in Acromegaly: An Altered Irisin Profile

Affiliations

Myokines in Acromegaly: An Altered Irisin Profile

Łukasz Mizera et al. Front Endocrinol (Lausanne). .

Abstract

Introduction: The muscle is an endocrine organ controlling metabolic homeostasis. Irisin and myostatin are key myokines mediating this process. Acromegaly is a chronic disease with a wide spectrum of complications, including metabolic disturbances.

Purpose: To examine the influence of acromegaly on irisin and myostatin secretion and their contribution to metabolic profile and body composition.

Materials and methods: In 43 patients with acromegaly and 60 controls, serum levels of irisin, myostatin, growth hormone (GH), insulin-like growth factor 1 (IGF-1), parameters of glucose, and lipid metabolism were determined. Body composition was assessed with dual-energy x-ray absorptiometry.

Results: The irisin concentration was significantly lower in patients with acromegaly compared to controls (3.91 vs. 5.09 μg/ml, p = 0.006). There were no correlations between irisin and GH/IGF-1 levels. In the study group, irisin was negatively correlated with fasting insulin (r = -0.367; p = 0.042), HOMA-IR (r = -0.510; p = 0.011), and atherogenic factors: Castelli I (r = -0.416; p = 0.005), Castelli II (r = -0.400; p = 0.001), and atherogenic coefficient (AC) (r = -0.417; p = 0.05). Irisin and myostatin concentrations were also lower in acromegalics with insulin resistance than without (2.80 vs. 4.18 μg/ml, p = 0.047; 81.46 vs. 429.58 ng/L, p = 0.018, respectively). There were no differences between study group and controls in myostatin concentration. Myostatin levels negatively correlated with GH (r = -0.306; p = 0.049), HOMA-IR (r = -0.046; p = 0.411), and insulin levels (r = -0.429; p = 0.016).

Conclusions: Decreased irisin concentrations in acromegaly may suggest impaired hormonal muscle function contributing to metabolic complications in this disorder. However, learning more about the association between myostatin and GH in acromegaly requires further studies. Nevertheless, it appears that myostatin is not critical for muscle mass regulation in acromegaly.

Keywords: GH; IGF-1; acromegaly; irisin; muscles; myokines; myostatin.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Pedersen BK, Febbraio MA. Muscles, Exercise and Obesity: Skeletal Muscle as a Secretory Organ. Nat Rev Endocrinol (2012) 8:457–65. doi: 10.1038/nrendo.2012.49 - DOI - PubMed
    1. Shimizu Y, Kielar D, Minokoshi Y, Shimazu T. Noradrenaline Increases Glucose Transport Into Brown Adipocytes in Culture by a Mechanism Different From That of Insulin. Biochem J (1996) 314:485–90. doi: 10.1042/bj3140485 - DOI - PMC - PubMed
    1. Lizcano F. The Beige Adipocyte as a Therapy for Metabolic Diseases. Int J Mol Sci (2019) 20:5058. doi: 10.3390/ijms20205058 - DOI - PMC - PubMed
    1. Xin C, Liu J, Zhang J, Zhu D, Wang H, Xiong L, et al. . Irisin Improves Fatty Acid Oxidation and Glucose Utilization in Type 2 Diabetes by Regulating the AMPK Signaling Pathway. Int J Obes (2016) 40:443–51. doi: 10.1038/ijo.2015.199 - DOI - PubMed
    1. Lee HJ, Lee JO, Kim N, Kim JK, Kim HI, Lee YW, et al. . Irisin, a Novel Myokine, Regulates Glucose Uptake in Skeletal Muscle Cells via AMPK. Mol Endocrinol (Baltimore Md.) (2015) 29:873–81. doi: 10.1210/me.2014-1353 - DOI - PMC - PubMed

Publication types